Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors

BOSTON, July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the treatment of pediatric brain tumors.

“We are pleased to report that this young child has tolerated the dosing regimen well,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. “Working with our colleagues at Northwestern University and Lurie Children’s Hospital, we continue to monitor this patient’s progress and are evaluating additional patients for enrollment in Chicago and at the other trial sites. For Ziopharm, this trial represents an additional clinical path for of Controlled IL-12, beyond the ongoing studies in recurrent glioblastoma (rGBM).” 

Stewart Goldman, M.D., Division Head Hematology-Oncology, Neuro-Oncology & Stem Cell Transplantation at Lurie Children's and investigator in the study, added, “One of the hallmark characteristics of DIPG is that immune cells cannot access the tumor, yet the microenvironment is not immunosuppressive. Therefore, driving T cells into this tumor could change the outcome for children with this lethal disease. Ziopharm’s data evaluating Controlled IL-12 in rGBM demonstrates that there is a sustained infiltration of activated T cells, turning “cold” tumors “hot” for months after veledimex dosing is finished. Extensive experience, as well as encouraging survival data associated with treating rGBM in adults, underscores our desire to evaluate Controlled IL-12 in children with gliomas, who currently lack viable treatment options.”

The phase 1/2 trial (NCT03330197) is designed to evaluate the safety and tolerability of a single intratumoral injection of Ad-RTS-hIL-12 given with up to 14 days of oral veledimex in children with gliomas. Up to 12 patients may be enrolled in phase 1 of the study, which is being conducted at leading pediatric cancer centers across the United States, including the Dana-Farber Cancer Institute in Boston and the University of California in San Francisco.

About DIPG
In children, the incidence of brain cancer is approximately 4.84 per 100,000, according to the National Cancer Institute. Glioma in the pontine region of the brain, or DIPG, accounts for approximately 10-15 percent of all cases of pediatric brain tumors, with about 150-300 new diagnoses per year in the United States.¹ Median survival ranges from 8-11 months.² There are no curative options.